JP2021512151A5 - - Google Patents
Info
- Publication number
- JP2021512151A5 JP2021512151A5 JP2020561589A JP2020561589A JP2021512151A5 JP 2021512151 A5 JP2021512151 A5 JP 2021512151A5 JP 2020561589 A JP2020561589 A JP 2020561589A JP 2020561589 A JP2020561589 A JP 2020561589A JP 2021512151 A5 JP2021512151 A5 JP 2021512151A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- antigen
- binding fragment
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024047473A JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620545P | 2018-01-23 | 2018-01-23 | |
| US62/620,545 | 2018-01-23 | ||
| PCT/US2019/014748 WO2019147670A1 (en) | 2018-01-23 | 2019-01-23 | B7-h4 antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024047473A Division JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512151A JP2021512151A (ja) | 2021-05-13 |
| JP2021512151A5 true JP2021512151A5 (https=) | 2022-01-31 |
| JPWO2019147670A5 JPWO2019147670A5 (https=) | 2022-01-31 |
Family
ID=67396234
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561589A Pending JP2021512151A (ja) | 2018-01-23 | 2019-01-23 | Ｂ７−ｈ４抗体およびその使用方法 |
| JP2024047473A Pending JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024047473A Pending JP2024075721A (ja) | 2018-01-23 | 2024-03-25 | Ｂ７－ｈ４抗体およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12286478B2 (https=) |
| EP (1) | EP3743447B1 (https=) |
| JP (2) | JP2021512151A (https=) |
| KR (1) | KR20200112913A (https=) |
| CN (2) | CN112566934B (https=) |
| AU (1) | AU2019211326B2 (https=) |
| BR (1) | BR112020014929A2 (https=) |
| CA (1) | CA3089469A1 (https=) |
| DK (1) | DK3743447T3 (https=) |
| ES (1) | ES2980171T3 (https=) |
| WO (1) | WO2019147670A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112566934B (zh) | 2018-01-23 | 2024-09-17 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
| JP7264337B2 (ja) * | 2019-03-21 | 2023-04-25 | スージョウ カノヴァ バイオファーマシューティカル カンパニーリミテッド | 抗ｂ７ｓ１ポリペプチドおよびその使用 |
| TWI821699B (zh) * | 2020-06-30 | 2023-11-11 | 大陸商諾納生物（蘇州）有限公司 | 抗b7h4抗體及其雙抗和應用 |
| JP2024501894A (ja) | 2021-01-04 | 2024-01-16 | メルサナ セラピューティクス インコーポレイテッド | Ｂ７ｈ４ターゲティング抗体－薬物コンジュゲートおよびその使用方法 |
| MX2023011310A (es) | 2021-03-26 | 2023-10-05 | Innate Pharma | Anclajes de citocina para proteinas de celulas nk de union a nkp46. |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| BR112023025331A2 (pt) | 2021-06-09 | 2024-02-27 | Innate Pharma | Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| WO2025128735A2 (en) * | 2023-12-11 | 2025-06-19 | Nextcure, Inc. | B7-h4 antibody-drug conjugates and methods of use thereof |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5190929A (en) | 1988-05-25 | 1993-03-02 | Research Corporation Technologies, Inc. | Cyclophosphamide analogs useful as anti-tumor agents |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| AU701578B2 (en) | 1992-08-21 | 1999-02-04 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| WO1994025591A1 (en) | 1993-04-29 | 1994-11-10 | Unilever N.V. | PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE) |
| US7411051B2 (en) | 1997-03-07 | 2008-08-12 | Human Genome Sciences, Inc. | Antibodies to HDPPA04 polypeptide |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| ATE413466T1 (de) | 1998-09-02 | 2008-11-15 | Diadexus Inc | Verfahren zur diagnose, bewertung sowie bilddarstellung verschiedener krebserkrankungen |
| US7888477B2 (en) | 1998-12-17 | 2011-02-15 | Corixa Corporation | Ovarian cancer-associated antibodies and kits |
| US6962980B2 (en) | 1999-09-24 | 2005-11-08 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of ovarian cancer |
| US6891030B2 (en) | 2000-07-27 | 2005-05-10 | Mayo Foundation For Medical Education And Research | T-cell immunoregulatory molecule |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| US7052694B2 (en) | 2002-07-16 | 2006-05-30 | Mayo Foundation For Medical Education And Research | Dendritic cell potentiation |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| DK1633784T3 (da) | 2003-05-09 | 2011-10-24 | Diadexus Inc | OVR110 antistofsammensætninger og -anvendelsesfremgangsmåder |
| US20070166281A1 (en) | 2004-08-21 | 2007-07-19 | Kosak Kenneth M | Chloroquine coupled antibodies and other proteins with methods for their synthesis |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN101355965A (zh) | 2005-06-08 | 2009-01-28 | 达纳－法伯癌症研究院 | 通过抑制程序性细胞死亡1（pd-1）途经治疗持续性感染和癌症的方法及组合物 |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| WO2007056539A2 (en) | 2005-11-08 | 2007-05-18 | Medarex, Inc. | Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy |
| EP2345412A1 (en) | 2005-12-02 | 2011-07-20 | The Johns Hopkins University | Use of high-dose oxazaphosphorine drugs for treating immune disorders |
| EP2109455A2 (en) | 2006-12-27 | 2009-10-21 | The Johns Hopkins University | Compositions and methods for stimulating an immune response |
| CN103536915A (zh) | 2006-12-27 | 2014-01-29 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| EA201000910A1 (ru) * | 2007-11-30 | 2011-04-29 | Бристоль-Мейерз Сквибб Компани | Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2011026122A2 (en) | 2009-08-31 | 2011-03-03 | Amplimmune, Inc. | B7-h4 fusion proteins and methods of use thereof |
| JP6120848B2 (ja) | 2011-08-15 | 2017-04-26 | メディミューン，エルエルシー | 抗ｂ７−ｈ４抗体およびその使用 |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| RU2015114772A (ru) | 2012-09-21 | 2016-11-10 | Санофи | Производные амида бензоимидазол-карбоновой кислоты в качестве модуляторов рецептора apj |
| AU2013361275B2 (en) * | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
| AU2014244424A1 (en) | 2013-03-14 | 2015-08-27 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| EP3177322A4 (en) | 2014-08-08 | 2018-07-18 | Alector LLC | Anti-trem2 antibodies and methods of use thereof |
| WO2016070001A1 (en) * | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
| CN112566934B (zh) | 2018-01-23 | 2024-09-17 | 奈斯科尔公司 | B7-h4抗体及其使用方法 |
-
2019
- 2019-01-23 CN CN201980021260.8A patent/CN112566934B/zh active Active
- 2019-01-23 DK DK19743902.9T patent/DK3743447T3/da active
- 2019-01-23 EP EP19743902.9A patent/EP3743447B1/en active Active
- 2019-01-23 CA CA3089469A patent/CA3089469A1/en active Pending
- 2019-01-23 CN CN202411212034.7A patent/CN119097699A/zh active Pending
- 2019-01-23 BR BR112020014929-2A patent/BR112020014929A2/pt unknown
- 2019-01-23 WO PCT/US2019/014748 patent/WO2019147670A1/en not_active Ceased
- 2019-01-23 KR KR1020207024024A patent/KR20200112913A/ko not_active Ceased
- 2019-01-23 ES ES19743902T patent/ES2980171T3/es active Active
- 2019-01-23 JP JP2020561589A patent/JP2021512151A/ja active Pending
- 2019-01-23 AU AU2019211326A patent/AU2019211326B2/en active Active
- 2019-01-23 US US16/964,133 patent/US12286478B2/en active Active
-
2024
- 2024-03-25 JP JP2024047473A patent/JP2024075721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512151A5 (https=) | ||
| Jin et al. | Emerging new therapeutic antibody derivatives for cancer treatment | |
| CN112739379B (zh) | 包含OX40抗原结合位点的Fc结合片段 | |
| TWI676681B (zh) | 具抗原專一性的t細胞及其用途 | |
| JP2021531754A5 (https=) | ||
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| HRP20230528T1 (hr) | Bispecifične molekule t stanica aktivirane proteazom | |
| JP2020501531A5 (https=) | ||
| US11993655B2 (en) | Anti-PD-L1 antibody and use thereof | |
| JP2019524693A5 (https=) | ||
| RU2013125459A (ru) | АНТИТЕЛА ПРОТИВ БЕЛКА РЕЦЕПТОРА c-Met | |
| CN112111012B (zh) | 共价多特异性抗体 | |
| KR20200092301A (ko) | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 | |
| WO2021216468A1 (en) | Human tigit specific single domain antibodies and methods of use | |
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| CA3155293A1 (en) | System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies | |
| JP2016529213A5 (https=) | ||
| JPWO2019147670A5 (https=) | ||
| JP2018525347A (ja) | 癌免疫療法に使用するための二重特異性抗体 | |
| CN117480178A (zh) | 嵌合FC-α受体及其用途 | |
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| JPWO2020218951A5 (https=) | ||
| JPWO2022217019A5 (https=) | ||
| US12054556B2 (en) | Anti-PD-L1 antibody and use thereof | |
| JP2024540604A (ja) | Ｃｄ１３７を標的とする二重特異性抗体、及び抗がん免疫療法のためのその使用 |